Back to the archiveResearch archive4D Molecular Therapeutics, Inc. Q1 2026 results4D Molecular Therapeutics, Inc. reported $3M of revenue in Q1 2026, up 21664.3% year over year, with diluted EPS of $-1.01 and an operating margin of -2416.1%. More on 4D Molecular Therapeutics, Inc. Company 4D Molecular Therapeutics, Inc. overview Facet Financials See how Top Bucket AI works for your firmRequest Demo Top Bucket AI Research Stay ahead of private markets Research and market intelligence for private-markets professionals. ✓ You're subscribed. Thanks for signing up. Dated reference snapshot as of September 10, 2026. This is not a live financial feed. Verify figures against primary filings before relying on them.